Focus Rheums| ACR Convergence 2024 Previews

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Related Articles

    CVS Health to Acquire Aetna for $69 billion

    (Reuters)—U.S. drugstore chain operator CVS Health Corp said on Sunday it had agreed to acquire U.S. health insurer Aetna Inc. for $69 billion, seeking to tackle soaring healthcare spending through lower-cost medical services in pharmacies. This year’s largest corporate acquisition will combine one of the nation’s largest pharmacy benefits managers (PBMs) and pharmacy operators with…

    Aetna CEO Warned It Would Cut Obamacare If Humana Deal Was Blocked

    NEW YORK (Reuters)—Aetna Inc.’s CEO said in a letter to the U.S. Department of Justice (DOJ) during the review of its deal to buy rival Humana Inc that the insurer would exit much of the individual Obamacare insurance market if the agency challenged the merger. In the July 5 letter, Chief Executive Officer Mark Bertolini…

    What the Affordable Care Act Means for Rheumatology

    Expected to flood the healthcare system with an influx of insured patients, Obamacare will likely exacerbate physician shortages, worsen capacity issues for many rheumatologists, and pressure providers to deliver a measurable quality of care, but analysts say rheumatology patients will benefit from expanded insurance coverage options

    Aetna, Seeking Antitrust Nod, Sells Medicare Drug Business to WellCare

    (Reuters)—Health insurer Aetna Inc said on Thursday it will sell its standalone Medicare prescription drug plan business to WellCare Health Plans Inc as it seeks U.S. antitrust approval for a planned acquisition by CVS Health Corp. The $69 billion CVS-Aetna deal would be the second large deal this year between insurers and pharmacy benefit managers,…